Transplantation, HomologousHematopoietic Stem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseHematologic NeoplasmsMyeloablative AgonistsGraft vs Tumor EffectBone Marrow TransplantationTransplantation, AutologousWhole-Body IrradiationUnrelated DonorsTissue DonorsTransplantation ChimeraGraft vs Leukemia EffectVidarabineHistocompatibility TestingTreatment OutcomePeripheral Blood Stem Cell TransplantationStem Cell TransplantationGraft SurvivalRecurrenceLeukemia, Myeloid, AcuteRetrospective StudiesHistocompatibilityCord Blood Stem Cell TransplantationBusulfanLiver TransplantationLeukemiaSiblingsSurvival AnalysisChimerismImmunosuppressive AgentsRemission InductionHLA AntigensMyelodysplastic SyndromesDonor SelectionSurvival RateAllograftsMinor Histocompatibility AntigensDisease-Free SurvivalGraft RejectionPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseKidney TransplantationCyclosporineHematologic DiseasesT-LymphocytesTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveImmunosuppressionFollow-Up StudiesCombined Modality TherapyTransplantation ImmunologyHematopoietic Stem CellsLymphocyte DepletionHeart TransplantationTransplantation, IsogeneicLymphoma, Non-HodgkinMycophenolic AcidLiving DonorsSalvage TherapyCyclophosphamideRisk FactorsCell TransplantationLung TransplantationTacrolimusChronic DiseaseMultiple MyelomaLymphomaTransplantationLymphoproliferative DisordersPrognosisHematopoietic Stem Cell MobilizationAntineoplastic AgentsCytomegalovirus InfectionsOrgan TransplantationAge FactorsIslets of Langerhans TransplantationLymphocyte TransfusionAntigens, CD34Cohort StudiesHepatic Veno-Occlusive DiseaseIncidenceMice, Inbred C57BLBone Marrow CellsAntineoplastic Combined Chemotherapy ProtocolsPancreas TransplantationCD8-Positive T-LymphocytesProspective StudiesAnemia, AplasticGranulocyte Colony-Stimulating FactorHematopoiesisAntilymphocyte SerumMelphalanLeukemia, MyeloidMice, Inbred BALB CDirected Tissue DonationNeoplasm, ResidualBlood Component RemovalTransplantation Tolerance